Asset Details
Do you wish to reserve the book?
Splenic marginal zone lymphoma: current knowledge and future directions
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Splenic marginal zone lymphoma: current knowledge and future directions
Do you wish to request the book?
Splenic marginal zone lymphoma: current knowledge and future directions
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Splenic marginal zone lymphoma: current knowledge and future directions
2012
Overview
Splenic marginal zone lymphoma (SMZL), along with extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) and nodal marginal zone lymphoma (NMZL), share a common origin from the \"marginal zone.\" However, these three entities display different clinical characteristics, reflecting probable biological variations according to the organ and cellular origin. Within the past decade, new data have been reported regarding pathogenic mechanisms as well as therapeutic advances. Clinically, SMZL presents as an indolent and disseminated disease at diagnosis, with a specific clinical presentation that includes predominantly splenomegaly, and in half of patients, autoimmune manifestations. Establishing the diagnosis may be difficult, especially distinguishing SMZL from other low-grade lymphomas, such as small B-cell lymphomas; however, recent findings have contributed to a better characterization of the disease, and the criteria for diagnosis have been improved. Therapeutic approaches consist of splenectomy or immunochemotherapy, but there is no consensus regarding the best treatment, except when SMZL is associated with hepatitis C virus infection. In this article, we review the current knowledge on the biological findings, clinical features, and therapeutic approaches for SMZL.
Publisher
Intellisphere, LLC,MultiMedia Healthcare Inc
Subject
/ Humans
/ Immunoglobulin Heavy Chains - genetics
/ Lymphoma, B-Cell, Marginal Zone - diagnosis
/ Lymphoma, B-Cell, Marginal Zone - etiology
/ Lymphoma, B-Cell, Marginal Zone - pathology
/ Lymphoma, B-Cell, Marginal Zone - therapy
/ Mutation
/ Splenic Neoplasms - diagnosis
/ Splenic Neoplasms - etiology
